Novo Nordisk A/S (NYSE:NVO) Position Increased by Silvercrest Asset Management Group LLC

Silvercrest Asset Management Group LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 3.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 127,998 shares of the company’s stock after buying an additional 3,881 shares during the period. Silvercrest Asset Management Group LLC’s holdings in Novo Nordisk A/S were worth $11,010,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its holdings in Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock worth $5,410,000 after buying an additional 23,223 shares in the last quarter. Bryn Mawr Capital Management LLC boosted its holdings in Novo Nordisk A/S by 358.8% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock worth $3,346,000 after buying an additional 30,420 shares in the last quarter. Clear Creek Financial Management LLC bought a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $450,000. DSM Capital Partners LLC boosted its holdings in Novo Nordisk A/S by 16.7% during the fourth quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company’s stock worth $172,678,000 after buying an additional 286,912 shares in the last quarter. Finally, Patrick M Sweeney & Associates Inc. lifted its position in shares of Novo Nordisk A/S by 81.2% in the 4th quarter. Patrick M Sweeney & Associates Inc. now owns 11,155 shares of the company’s stock valued at $960,000 after acquiring an additional 5,000 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on NVO shares. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 25th. Dbs Bank downgraded shares of Novo Nordisk A/S to a “sell” rating in a research report on Friday, April 25th. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, BNP Paribas started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an “underperform” rating for the company. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $135.00.

Novo Nordisk A/S Stock Down 2.7%

NVO stock opened at $64.35 on Friday. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company has a market cap of $288.75 billion, a price-to-earnings ratio of 19.56, a PEG ratio of 0.90 and a beta of 0.65. The company has a 50 day moving average of $67.31 and a two-hundred day moving average of $84.38.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion during the quarter. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.